STOK: stoketherapeutics.com O‘sish sur’atiga tuzatilgan narx-foyda
Stoke Therapeutics (STOK) barqaror daromadlar yetishmasligi sababli hozirda tashqi moliyalashtirishga tayanmoqda. P/E o'sish tendentsiyasi ushbu holatni aks ettiradi, bunda 0.00 ushbu parametrning joriy darajasini belgilaydi. Epilepsiya davolash uchun TANGO patentlari o'sishni qo'llab-quvvatlamoqda, garchi murakkab kriyo-logistik dori yetkazib berish zanjirlari xarajatlarni oshirayotgan bo'lsa-da.
Stoke Therapeutics (STOK) kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- aksiyadorlik kapitalining balans qiymati ma'lumotlari:
- biznesning qarz tarkibi va likvidligi tafsilotlari:
Barcha qarzlarning o‘z mablag‘lariga nisbati Stoke Therapeutics|STOK - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati stoketherapeutics.com|STOK - Kompaniya qarzlari|Qarzning sof aktivlarga nisbati Stoke|STOK - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzlari Stoke Therapeutics|Kritik likvidlik koeffitsiyenti stoketherapeutics.com
- foyda va qiymat multiplikatorlari haqida ma'lumot:
STOK - Sof foyda|Kutilayotgan sof foyda Stoke Therapeutics|STOK - Narx-foyda koeffitsiyenti|Forvard P/E multiplikatori Stoke Corp|STOK - Narx-foyda va o‘sish multiplikatori|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati koeffitsiyenti Stoke|STOK - EBITDA operatsion foydasi|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Stoke Therapeutics|STOK - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi stoketherapeutics.com|STOK - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi Stoke Therapeutics
Kompaniyaning fundamental tahlili:Stoke Therapeutics Inc, STOK
Ushbu ko'rsatkich joriy P/E koeffitsientini foyda o'sish sur'atlari bilan solishtiradi va aktivning dinamikasiga asoslanib uning adolatli qiymatini aniqlash imkonini beradi. PEG koeffitsientining tahlili Stoke Therapeutics (STOK) kompaniyasining yashirin salohiyatini aniqlashga yordam beradi, uning noyob RNK terapiyasi tasdiqlangach, kamyob epilepsiya davolashda bemorlarni saqlab qolishning eng yuqori darajasiga ega bo'lgan monopol ekotizimni yaratadi.
Raqobatdosh kompaniyalar
PEG multiplikatori Tempus AI, Inc (TEM)|PEG multiplikatori QGEN (Qiagen Group)|Isis Pharmaceuticals (IONS) - O‘sish sur’atiga tuzatilgan narx-foyda|RGEN: Narx-foyda va o‘sish multiplikatori|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti RNA (aviditybiosciences.com)|CRSP (CRISPR Therapeutics) - Narx-foyda va o‘sish multiplikatori|WGS: Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|RARE (Ultragenyx Pharma) - PEG multiplikatori|BEAM: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori SRPT|TWST - O‘sish sur’atiga tuzatilgan narx-foyda|Narxning foydaga va o‘sish sur’atiga nisbati 10x Genomics TXG|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti NTLA|BioLife Corp - PEG multiplikatori|WVE - PEG multiplikatori|Maze Therapeutics Inc (MAZE) - Narxning foydaga va o‘sish sur’atiga nisbati|Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati SION (sionnatx.com)|PRME (Prime Medicine) - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda Taysha Gene Therapies Inc TSHA|Narx-foyda va o‘sish multiplikatori QURE (uniQure Corp)|PEG multiplikatori MeiraGTx Corp (MGTX)|REGENXBIO Inc. - Narx-foyda va o‘sish multiplikatori|Kompaniya qiymatining foyda o‘sish sur’atiga nisbati SLDB (solidbio.com)|Ocugen - PEG multiplikatori|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Pacific Biosciences of California, Inc. PACB|BNTC: PEG multiplikatori|Narx-foyda va o‘sish multiplikatori Design Corp|Narxning foydaga va o‘sish sur’atiga nisbati Rocket Pharmaceuticals|4dmoleculartherapeutics.com (FDMT) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati Lexeo Therapeutics (LXEO)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati korrobio.com|Editas - Narx-foyda va o‘sish multiplikatori|Kompaniya qiymatining foyda o‘sish sur’atiga nisbati SLN (Silence Therapeutics Corp)|PRQR - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atiga tuzatilgan narx-foyda Codexis, Inc.|Sangamo Therapeutics, Inc. (SGMO) - Narxning foydaga va o‘sish sur’atiga nisbati|Nautilus Bio (NAUT) - PEG multiplikatori|MGX (Metagenomi, Inc) - PEG multiplikatori|O‘sishni hisobga olgan narx-foyda koeffitsiyenti DTIL (Precision BioSciences Inc.)|Narxning foydaga va o‘sish sur’atiga nisbati Generation Bio Co. (GBIO)|boundlessbio.com - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|PEG multiplikatori XCUR (Exicure)|PEG multiplikatori Imunon Inc IMNN|PHIO - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Mustang Bio, Inc. MBIO|RNAZ (transcodetherapeutics.com) - Narx-foyda va o‘sish multiplikatori|BNGO: Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati Applied DNA Sciences, Inc.|O‘sish sur’atiga tuzatilgan narx-foyda bluebird bio Inc. BLUE|Narxning foydaga va o‘sish sur’atiga nisbati ImmunoPrecise Antibodies (IPA)|PEG multiplikatori Omega Therapeutics Corp (OMGA)|PEG multiplikatori OMIC (Singular Genomics Systems)|regulusrx.com (RGLS) - O‘sish sur’atiga tuzatilgan narx-foyda|SYRS: Narx-foyda va o‘sish multiplikatori|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti TBIO (Telesis Bio Inc.)|TCON (TRACON) - Narx-foyda va o‘sish multiplikatori|UBX: Kompaniya qiymatining foyda o‘sish sur’atiga nisbati
